Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes

被引：0
|
作者：
A. Hemeryck
C. De Vriendt
F. M. Belpaire
机构：
[1] Heymans Institute of Pharmacology,
[2] University of Gent Medical School,undefined
[3] 9000 Gent,undefined
[4] Belgium e-mail: frans.belpaire@rug.ac.be Tel.: +32-9-2403355; Fax: +32-9-2404988,undefined
来源：
European Journal of Clinical Pharmacology | 1999年 / 54卷
关键词：
Key words CYP2C9; SSRI; (S)-warfarin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To investigate the in vitro potential of selective serotonin reuptake inhibitors (SSRIs) to inhibit two CYP2C9-catalysed reactions, tolbutamide 4-methylhydroxylation and (S)-warfarin 7-hydroxylation.
引用
收藏
页码：947 / 951
页数：4
相关论文
共 50 条
  • [31] Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively
    Wen, X
    Wang, JS
    Backman, JT
    Laitila, J
    Neuvonen, PJ
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (06) : 631 - 635
  • [32] Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes
    Ho, PC
    Abbott, FS
    Zanger, UM
    Chang, TKH
    PHARMACOGENOMICS JOURNAL, 2003, 3 (06): : 335 - 342
  • [33] Effects of acid and lactone forms of statins on S-warfarin 7-hydroxylation catalyzed by human liver microsomes and recombinant CYP2C9 variants (CYP2C9.1 and CYP2C9.3)
    Shiozawa, Ayaka
    Yamaori, Satoshi
    Kamijo, Shinobu
    Ohmori, Shigeru
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 36
  • [34] Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes
    P C Ho
    F S Abbott
    U M Zanger
    T K H Chang
    The Pharmacogenomics Journal, 2003, 3 : 335 - 342
  • [35] Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats
    He, Hui
    Zhang, Yuandong
    Zhao, Dezhang
    Jiang, Junhao
    Xie, Baogang
    Ma, Limei
    Liu, Xueqing
    Yu, Chao
    XENOBIOTICA, 2020, 50 (08) : 939 - 946
  • [36] Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance
    Shaul, Chanan
    Blotnick, Simcha
    Adar, Liat
    Muszkat, Mordechai
    Bialer, Meir
    Caraco, Yoseph
    CLINICAL PHARMACOKINETICS, 2022, 61 (08) : 1187 - 1198
  • [37] THE EFFECTS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND THEIR METABOLITES ON S-MEPHENYTOIN 4'-HYDROXYLASE ACTIVITY IN HUMAN LIVER-MICROSOMES
    KOBAYASHI, K
    YAMAMOTO, T
    CHIBA, K
    TANI, M
    ISHIZAKI, T
    KUROIWA, Y
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (05) : 481 - 485
  • [38] Polysaccharide peptides from Coriolus versicolor competitively inhibit tolbutamide 4-hydroxylation in specific human CYP2C9 isoform and pooled human liver microsomes
    Yeung, John H. K.
    Or, Penelope M. Y.
    PHYTOMEDICINE, 2011, 18 (13) : 1170 - 1175
  • [39] Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance
    Chanan Shaul
    Simcha Blotnick
    Liat Adar
    Mordechai Muszkat
    Meir Bialer
    Yoseph Caraco
    Clinical Pharmacokinetics, 2022, 61 : 1187 - 1198
  • [40] Theoretical Studies on the Substrate Binding Mode and Regioselectivity of Human CYP2C9 with S- and R-Warfarin
    Wu Yunjian
    Cut Yinglu
    Zheng Qingchuan
    Zhang Hongxing
    CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE, 2014, 35 (12): : 2605 - 2611
12345